William Noyes, MD
Radiation Oncology · Grand Forks, NDNPI 1649382292
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (56.5%), ownership interests and food and beverage — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 99.5% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2020 at $798,065 and has fallen 99.4% since, to $4,805 in 2025. Among radiation oncology clinicians in ND with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 342 payments — averaging $5428.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1.8M
- Onmark, Inc.$3K
- US Oncology Corporate, Inc.$842
- Johnson & Johnson$541
- AstraZeneca$454
- Daiichi Sankyo Inc.$371
- plus $4K from 54 others
What the payments were for
- Travel & lodging$2,3220%
- Food & beverage$7,5480%
- Education$210%
- Gifts$530%
- Ownership interest$797,70643%
- Other$1,048,78556%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$1,846,491
How this compares
$1,856,434 in reported general payments places this provider in the 95th percentile of 20 radiation oncology providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bicalutamide | 13 | $247 |
| Tamsulosin Hcl | 26 | $240 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Grand Forks
- Grant SeegerGrand Forks$31K
- Marshall WinchesterGrand Forks$0
- Jacob WynneGrand Forks$0
- Robert ReynoldsBismarck$2K
- Joon LeeBismarck$1K
- Michael GrantMinot$1K
- Salah DajaniFargo$508
- Jason HirshbergMinot$290
- Sommer NurkicFargo$216
- Elliot LawrenceFargo$157
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.